STANDARD BIOTOOLS INC. (LAB) 8-K Current Report: February 24, 2026
Filed: February 24, 2026
Health Care
Laboratory Analytical InstrumentsSTANDARD BIOTOOLS INC. (LAB) 8-K current report filed with SEC EDGAR on February 24, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 2.02: Results of Operations and Financial Condition
- Item 7.01: Regulation FD Disclosure
STANDARD BIOTOOLS INC. 8-K Feb 24, 2026 Event Analysis
Item 2.02 · Results of Operations and Financial Condition
- • Q4/full-year 2025 earnings release filed February 24, 2026, signed by CFO Alex Kim
- • No financial figures included in 8-K body — refer to attached press release exhibit for actual results
Item 7.01 · Regulation FD Disclosure
- • Full year 2026 revenue outlook disclosed via Reg FD — specific guidance figures contained in the referenced exhibit
- • Reg FD disclosure ensures simultaneous public access to forward-looking revenue guidance material to valuation
- • Investors should review the attached exhibit for the actual 2026 revenue figures and any assumptions underlying the outlook
Get deeper insights on STANDARD BIOTOOLS INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.